OMEROS CORP Investment Income, Interest
OMEROS CORP (OMER) reported Investment Income, Interest of $2.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-03-31
- OMEROS CORP investment income, interest for the quarter ending 2025-03-31 was $700.00K, a 75.00% decline year-over-year.
- OMEROS CORP investment income, interest for the quarter ending 2024-12-31 was $1.30M, a 56.67% decline year-over-year.
- OMEROS CORP investment income, interest for the quarter ending 2024-09-30 was $1.80M, a 55.00% decline year-over-year.
- OMEROS CORP investment income, interest for the quarter ending 2024-06-30 was $2.50M, a 40.48% decline year-over-year.
- OMEROS CORP investment income, interest for fiscal 2025 was $2.30M, a 72.62% decline from fiscal 2024.
- OMEROS CORP investment income, interest for fiscal 2024 was $8.40M, a 42.86% decline from fiscal 2023.
- OMEROS CORP investment income, interest for fiscal 2023 was $14.70M, a 568.18% increase from fiscal 2022.
- OMEROS CORP investment income, interest for fiscal 2022 was $2.20M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.30M 10-K · filed 2026-03-31 | |||
| 2025-03-31 | $700.00K 10-Q · filed 2025-05-15 | $2.00M derived: sum of 2 quarters · filed 2026-03-31 | $3.80M derived: sum of 3 quarters · filed 2026-03-31 | $6.30M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.10M derived: sum of 2 quarters · filed 2026-03-31 | $5.60M derived: sum of 3 quarters · filed 2026-03-31 | $8.40M 10-K · filed 2026-03-31 |
| 2024-09-30 | $1.80M 10-Q · filed 2024-11-13 | $4.30M derived: sum of 2 quarters · filed 2024-11-13 | $7.10M 10-Q · filed 2024-11-13 | $10.10M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-06-30 | $2.50M 10-Q · filed 2024-08-07 | $5.30M 10-Q · filed 2024-08-07 | $8.30M derived: sum of 3 quarters · filed 2026-03-31 | $12.30M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-03-31 | $2.80M 10-Q · filed 2025-05-15 | $5.80M derived: sum of 2 quarters · filed 2026-03-31 | $9.80M derived: sum of 3 quarters · filed 2026-03-31 | $14.00M derived: sum of 4 quarters · filed 2026-03-31 |
| 2023-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $7.00M derived: sum of 2 quarters · filed 2026-03-31 | $11.20M derived: sum of 3 quarters · filed 2026-03-31 | $14.70M 10-K · filed 2026-03-31 |
| 2023-09-30 | $4.00M 10-Q · filed 2024-11-13 | $8.20M derived: sum of 2 quarters · filed 2024-11-13 | $11.70M 10-Q · filed 2024-11-13 | $13.80M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $4.20M 10-Q · filed 2024-08-07 | $7.60M 10-Q · filed 2024-08-07 | $9.80M derived: sum of 3 quarters · filed 2024-08-07 | $10.20M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $3.40M 10-Q · filed 2024-05-15 | $5.60M derived: sum of 2 quarters · filed 2024-05-15 | $6.00M derived: sum of 3 quarters · filed 2024-05-15 | $6.20M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $2.20M 10-Q · filed 2023-05-09 | $2.60M derived: sum of 2 quarters · filed 2023-11-09 | $2.80M derived: sum of 3 quarters · filed 2023-11-09 | $2.20M 10-K · filed 2025-03-31 |
| 2022-09-30 | $400.00K 10-Q · filed 2023-11-09 | $600.00K derived: sum of 2 quarters · filed 2023-11-09 | $600.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $200.00K 10-Q · filed 2023-08-09 | $200.00K 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |